The Science of ‘Man Flu’: Zika Study Adds to Evidence for Sex-specific Immune Responses

Biological sex played a significant role in determining the severity of disease following Zika virus infection, McMaster researchers find.

Photo by Brittany Colette on Unsplash

That men tend to suffer more than women when they get sick is an age-old cliché. But a growing body of research suggests that there may be some truth to it.

In a new study out of McMaster University, researchers found that biological sex played a significant role in determining the severity of disease following Zika virus infection.

The findings, published in the Journal of Infectious Diseases, build on recent studies that have shown males are more likely to experience severe outcomes from viral infections, including COVID-19, influenza and West Nile.

Principal investigator Ali Ashkar, a professor of Medicine at McMaster, suggests the vastly different outcomes have less to do with the viruses or infections themselves and more to do with how we respond to them.

“It’s becoming more and more accepted in the field that the outcomes of acute viral infections typically differ between males and females,” he says.

“The male immune system seems to respond more strongly to these infections, and as a consequence, the damage or inflammation to the site of infection is often more severe.”

Ashkar’s group, led by PhD student Alexa Mansour, investigated biological sex as a determinant of severe Zika disease by monitoring infected male and female mice. In doing so, they found that male mice were significantly more susceptible to severe neurological complications, including weakness and paralysis, than their female counterparts were.

The researchers say one of the most striking findings was that the difference in disease severity couldn’t be explained away by the amount of virus replicating in the animals’ bodies.

Ashkar, a member of the Michael G. DeGroote Institute for Infectious Disease Research, says his team initially suspected the male subjects must have had higher levels of the virus – that perhaps the female immune system was clearing the virus quicker, before severe disease could manifest; however, further testing revealed that the male and female mice had comparable levels of Zika in both their blood and brains.

“Both the males and females were infected under the same conditions – they were nearly genetically identical, they were the exact same age, and they were infected with the same virus taken from the same vial at equal amounts,” Ashkar says. “It made no sense for there to be such a huge difference in how the disease presented.”

Mansour, who first-authored the new paper, says the findings were almost completely by chance: The lab had been studying Zika in mice over an extended period of time, when suddenly the virus’s trademark neurological symptoms stopped presenting.

Quickly, they realized that all of the mice in the test cohort were female. When they re-introduced male mice to the study, the severe neurological complications returned.

“We weren’t initially convinced that biological sex was behind the lack of symptoms,” Mansour says. “We asked ourselves, ‘Are we doing something wrong?’ ‘Are the mice somehow not getting infected?’ But when we began infecting male mice again and the symptoms returned, it became clear what was happening.”

Mansour says the findings, coupled with the growing body of related scientific literature, suggest that “it’s really important to consider biological sex in the context of infectious disease going forward.”

For Ashkar, that consideration is something that should extend beyond just research and factor into clinical care.

“From now on, for any acute viral infection, it’s important for physicians to control inflammation early in male patients,” Ashkar says.

“We already have a lot of approved and effective anti-inflammatory medications, so we don’t necessarily need new interventions to do this. We just need to acknowledge that male patients might be more susceptible to severe disease and tailor our treatment plans accordingly.”

By Blake Dillon, Faculty of Health Sciences November 17, 2026

Source: McMaster University

Born Too Soon in a Warming World

Photo by William Fortunato on Pexels

By Lebohang Radebe and Darshnika Lakhoo for Spotlight

Southern Africa is considered a ‘hotspot’, warming faster than the global average. Add the current El Niño event, and the health risks to mothers and babies this summer are sky high. Lebohang Radebe and Darshnika Lakhoo consider what individuals and the state can do to mitigate these risks.

Search online for climate change, or extreme heat, and you will find melting ice, cracked earth, burning forests, and polar bears. You will find surprisingly few human faces.

This is a blind spot. Speaking at COP31 in Turkiye, currently under way, Wellcome Trust’s head of climate change, Alan Dangor, put it plainly.

“The state of the climate is now in reality the biggest indicator of the state of human health.”

Heat in pregnancy has drawn growing attention at this year’s Cop talks. A global call to action, Birthright, was announced which urges governments to protect pregnant women from rising temperatures.

In line with World Prematurity Day that was held on 15 November, we want to focus on one outcome in particular: preterm birth, defined as birth before 37 weeks of gestation. It is the leading cause of death in children under 5 years of age. This day reminds us how many babies are born too soon, and how unequal that burden falls.

Progress in reducing preterm birth has stalled over the last decade and climate change is one of the reasons. So, what does it mean to be born too soon in a rapidly warming world?

Heat is already harming pregnant women and newborns

Over 84 studies worldwide have explored the relationship between heat and preterm birth. The vast majority find that heat causes harm.

The risk rises with both heat waves and general increases in temperature. Our review found that women exposed to a heatwave had a 26% higher odds – a statistical measure that describes how often a preterm birth occurs in a group exposed to heat versus a group that was not exposed – of a preterm birth than those who were not. Similarly, at higher versus lower heat, we found a 12% higher odds.

The burden is not shared equally. In low-income countries, the odds of a preterm birth were 1.61 times higher compared to 1.11 higher odds in high-income countries when exposed to higher versus lower temperatures. Those hardest hit are the countries that contributed the least to climate change and are the least able to cope with it.

Closer to home, research from Soweto has found similar harmful effects. While we still don’t know the exact causes linking heat to preterm birth, ongoing research – including a study conducted by our team at Wits Planetary Health Research – are looking to establish this link.

Heat is not a future threat, it is already putting mothers and babies at risk, in South Africa and worldwide.

A double threat this summer

Heat is not new to this region. Our elders and ancestors have always known and experienced extreme heat, with many heat-resilient strategies built into indigenous ways of living, from housing construction to water management, and farming practices.

But our climate is changing. Southern Africa is considered a ‘hotspot’, warming faster than the global average. We now experience higher temperatures, more often, and for longer periods than our ancestors did.

This summer adds the strongest-ever recorded El-Nino event. Expect lower than normal rainfall and higher than normal temperatures in the region with a risk of drought. Together, climate change and El Niño put babies at very high risk of being born too soon.

What women and communities can do

We can empower pregnant women and the people around them to take precautions. Anyone pregnant with warning signs should go to a health facility immediately. These include headache, nausea, vomiting, blurred vision, dizziness, fainting or confusion, labour pains before the due date, bleeding or waters breaking, reduced movements from the baby or swelling in hands and face.

Listen to weather warnings and keep a water bottle nearby. Drink often, especially when thirsty, breastfeeding or when it’s hot. Wear light, loose-fitting clothing, and a hat in the sun, and avoid outdoor and strenuous work during the hottest hours of the day.

Cool down with whatever is available. Feet in cool water, a wet cloth or damp clothing, a cold bath. Seek shade or cool indoor spaces such as shopping malls, open windows at night, rest with your feet raised, and ask for help.

What governments must do

Individual precautions are not enough. Maternal and child health are the heart of any health system, and the complications from being born too soon, including heart and lung disease, and developmental delays, can last a lifetime.

Government should prioritise both emergency and long-term sustainable funding to maternal and neonatal care. Ring-fenced emergency health funds are needed now to meet the anticipated rise in demand for maternal and neonatal services this summer, so that premature babies have a chance to survive and mothers are adequately cared for.

Sustainable, long-term funding is needed to build climate-resilient health systems that can withstand rising temperatures at the individual, household, community, and health facility level. This also includes routine tracking of premature birth in our healthcare system. In the longer term, South Africa needs a just transition away from fossil fuels to tackle the root cause of the climate crisis.

The timing matters. The World Health Organisation, together with partners, have just published a guideline on heat-health monitoring for maternal and child health. It recommends that countries prioritise tracking preterm birth as a key indicator.

With urgent action now, we can reduce the number of babies being born too soon in a warming world.

*Radebe is the Director for South Africa at Wits Planetary Health Research, and the South Africa Director for the Southern Africa Consortium for Climate Change and Health. Lakhoo is a Senior Research Clinician at Wits Planetary Health Research and a mother to premature babies.

*This article was first published by Spotlight – health journalism in the public interest. Sign up to the Spotlight newsletter.

Digital Weight Management Works Best When a Doctor Still Leads the Plan

Photo by I Yunmai on Unsplash

18 November 2026: Managing obesity involves hundreds of everyday decisions that happen outside the doctor’s consulting room. That is a heavy burden for someone already dealing with a complex and demanding health reality, says Dr Gerhard Vosloo, Founder and Head Consulting Practitioner at Dr GL Vosloo Medical Practice, managed by BioWell.

“Doctors can give patients clear guidance during a consultation, but patients still have to carry that guidance into the choices they make throughout every ordinary day. Digital health tools can help close that gap by giving people practical ways to monitor their progress, remain connected to medical guidance, and keep following a structured weight-management programme when the pressures of daily life make consistency difficult.

“It should, however, remain part of a treatment plan developed and overseen by a qualified medical practitioner. An app can help someone recognise changes in their health or keep track of their progress, but, on its own, it cannot determine the cause of a medical problem, establish whether prescription treatment is appropriate, or make clinical decisions on the patient’s behalf. Those decisions need a doctor who remains accountable for them.”

Digital tools can make a difference if chosen wisely

Dr Vosloo explains that the value of digital health depends on what a tool helps patients accomplish and how effectively it supports their medical care. He suggests considering five practical factors when choosing an app, wearable device, or digital weight-management programme.

1.     Look for useful ways to monitor progress

Weight changes are only part of a much larger picture. Recording eating patterns, physical activity, sleep, energy levels, and other relevant health information can help patients identify trends they might otherwise overlook. Wearable devices can add useful estimates of daily movement, activity, and sleep, although their readings are not comparable to proper clinical measurements.

The information becomes particularly valuable when patients can discuss it with their doctor and use it to understand why progress may have slowed, why certain symptoms are developing, or where changes to their routine could help.

2.     Choose tools that make healthy routines easier to sustain

Reminders can help people maintain regular meals, exercise commitments, follow-up appointments, and other aspects of their treatment plan. For someone balancing work, family responsibilities, and the demands of managing obesity, having that structure available on a phone can make consistency considerably easier.

Dr Vosloo notes, “The most useful reminders are those tailored to the patient’s actual circumstances and treatment goals. If an app constantly demands attention or sets daily targets that simply do not fit a person’s life, it can quickly become yet another burden they are expected to carry. That frustration can defeat the very purpose the technology is meant to serve.”

3.     Make sure there is a connection to professional medical care

Digital consultations and patient-management platforms like BioWell that are managed by a professional medical team can help people access medical guidance without travelling to a consulting room every time they need advice. They can also give doctors more regular insight into how treatment is progressing, particularly when patients report symptoms, side effects, or difficulties following their programme.

However, online consultations and digital monitoring have limits. Some concerns still require physical examinations, laboratory testing, or urgent medical attention. Patients need to know when to contact their doctor directly and how to obtain in-person care when necessary.

4.     Check the quality of the medical information

A popular app is not necessarily a medically reliable one, warns Dr Vosloo. “An attractive design, thousands of downloads, and favourable customer reviews say little to nothing about whether its advice is medically accurate or appropriate for someone managing obesity.”

A May 2026 study published in the International Journal of Obesity screened 1,220 app listings and evaluated 21 listings representing 18 different obesity-management apps. Only one of those 18 apps had documented scientific evaluation. This does not mean the others were ineffective, but it highlights how limited the available scientific evidence can be among digital tools.

Patients should therefore establish who developed the tool, whether qualified medical professionals are involved, and whether its recommendations are grounded in recognised clinical evidence. AI-generated advice deserves particular care, especially when it concerns medication, symptoms, or changes to treatment. Patients should also always ask whether a doctor is accountable for what the tool tells them.

5.     Find out who can see your health information

Beyond physical wellbeing, patients should also consider how an app protects their personal data. Weight, eating habits, sleep, and symptoms are deeply personal, and digital health tools may store years of this information – data most people do not want to be shared with others without their knowledge and explicit consent.

Patients have every right to know where those records are stored, who can access them, and whether any of that data is shared with or sold to third parties. If a tool is linked to a medical practice, that information must be guarded with the same seriousness and confidentiality as any patient file.

Dr Vosloo believes the greatest opportunity for digital health ultimately lies in bringing these capabilities together within structured medical care, particularly for patients who struggle to access regular consultations because of distance, cost, or demanding schedules.

“Technology allows us to support patients far more consistently than occasional consultations alone. As these tools become more capable, it matters even more that doctors shape how they’re built and remain accountable for how they’re used. The real test is whether it helps doctors understand what is happening between appointments and gives patients the support they need to make meaningful progress in their everyday lives,” he concludes.

Daily Iron Supplements Reduce Iron Deficiency Anaemia in Children and Adolescents

Photo by Ben Wicks on Unsplash


Giving children and adolescents a daily iron tablet significantly reduces the risk of iron deficiency anaemia with little to no effect on several common illnesses, according to a Cochrane review of 114 studies involving more than 50 000 participants.

Iron deficiency occurs when the body lacks enough iron for its needs. These include making haemoglobin, the protein in red blood cells that carries oxygen from the lungs to the rest of the body. Left untreated, it leads to iron deficiency anaemia. 

Iron supplementation is the standard of care for the prevention and treatment of anaemia in many parts of the world particularly for adolescents and women. Previous evidence has pointed to the benefits of iron supplementation for improving iron deficiency anaemia in children. However, current World Health Organization guidelines, last updated in 2016, emphasize the gap in evidence on the long-term effects. 

Led by researchers from Cornell Joan Klein Jacobs Center for Precision Nutrition and Health at Cornell University, the review included 114 studies with over 50,000 children and adolescents, looking at the effects of daily oral iron, alone or with folic acid or when other vitamins and minerals were added. Many of the studies were conducted in Asia and focused on children under five years of age.

Daily iron reduces the risk of iron deficiency anaemia 

Findings from this review demonstrate that iron alone probably reduces iron deficiency anaemia compared with no intervention or placebo. Iron with folic acid probably reduces it too, although this finding rests on a single study, and iron with other vitamins and minerals also may reduce it. For anaemia and iron deficiency more broadly, there is some evidence that iron may be useful for reducing both. 

Iron alone had no effect on how tall a child is or how much they weigh, compared with other children of the same age and sex. It also had no effect on several common illnesses, such as cough, fever or respiratory illness, and iron with folic acid makes little to no difference to diarrhoea or respiratory illness. Findings for other combinations ranged from moderate to very low certainty. 

“Iron deficiency remains one of the most common nutritional problems affecting children worldwide,” says first author Dr Kripa Rajagopalan. “Our review shows that daily iron supplements do what they are meant to do, which is reduce iron deficiency anaemia, without any measurable impact on the common illnesses parents and health workers worry about.” 

Side effects are mostly mild, but evidence is uncertain 

The evidence on side effects was unclear for some outcomes. Iron may increase stool discolouration. Iron alone may make little to no difference to vomiting or diarrhoea, and the effect on constipation is very uncertain. Iron combined with other vitamins and minerals probably increases vomiting compared with the same supplement without iron.

Senior author Dr Saurabh Mehta explains: “While the evidence base supports the use of daily iron supplements where needed, some adverse effects do occur. Stool discolouration and, in some formulations, vomiting were more common with iron, and the certainty of evidence for several outcomes, including anaemia and iron deficiency themselves, was low or very low.” 

Anaemia remains a major global burden for young children

Anaemia affects an estimated 874 million children and women worldwide; the greatest burden is seen among young children, with 40% of children younger than five years affected in 2019. Approximately half of these cases are due to iron deficiency. Reducing anaemia is a key goal of the 2030 Global Strategy for Women’s, Children’s and Adolescents’ Health. 

“These findings give decision-makers a stronger evidence base for guidance on iron supplementation in children and adolescents,” says co-author Dr Julia L. Finkelstein. “The data supports continued use of iron supplementation where iron deficiency is a concern.”

The authors stress that the findings support iron supplementation but should not be read as meaning every child or adolescent needs daily iron supplements. They should be interpreted in light of individual nutritional needs, the prevalence of iron deficiency and anaemia, and the formulation of the supplement.

By Mia Parkinson

Read the full review

Source: Cochrane

Chronic Disease is Getting Younger. South Africa Cannot Afford to Ignore it

By Lee Callakoppen, Principal Officer of Bonitas Medical Fund

Photo by Hush Naidoo on Unsplash

When we think about chronic disease, most of us picture someone in their sixties or seventies. Someone who has spent decades working, raising a family and perhaps not paying as much attention to their health as they should have. We tend to associate conditions such as hypertension, diabetes and heart disease with getting older.

But what happens when the person being admitted to hospital for hypertension is just 11 years old? That is the age of the youngest member recorded in Bonitas’ hypertension-related hospital admissions data. It is an extraordinary statistic, and one that has stayed with me.

Of course, a single case does not tell us everything about the state of our nation’s health. But it does challenge something many of us have come to accept: that chronic disease is largely a problem for later in life. The reality is that the warning signs are appearing much earlier, and I believe we need to pay closer attention to what they are telling us.

The warning signs are closer than we think

South Africa is already carrying a significant burden of chronic disease. According to the International Diabetes Federation, approximately one in nine adults is living with diabetes, with many cases remaining undiagnosed. The South African Medical Research Council (SAMRC)

estimates that hypertension affects almost half of adult women and around 34% of adult men.

These figures are concerning enough on their own. What worries me more, however, is what happens when these risks begin to overlap, particularly among people who may otherwise consider themselves young and healthy.

At Bonitas, our wellness screening data offers an interesting perspective on this. Nearly three-quarters of screened participants had at least one elevated health risk marker. More than half were classified as obese, almost a quarter had elevated blood pressure, and 43% of those identified as being at risk presented with two or more cardiometabolic risk factors.

What caught my attention was that 71% of the elevated risk markers identified were among members younger than 50.

Now, that doesn’t necessarily mean younger people are at greater risk than older people. But it does tell us that these health concerns are very much present during the years when people are building careers, raising children, paying bonds and generally getting on with life.

And perhaps that is part of the problem.

When you’re in your thirties or forties, managing work deadlines, school runs and household responsibilities, your health can easily become something you promise yourself you’ll pay attention to later. You feel relatively fine, so you assume everything is fine.

Yet hypertension, for example, can develop without obvious symptoms. By the time someone realises there is a problem, the condition may already require ongoing medical management.

Our hospital admissions data brings this into sharper focus. Of more than 2,700 hypertension-related admissions recorded, approximately one-third involved members younger than 50, while one in eight involved members under 40.

These are not necessarily the ages at which most people expect to find themselves dealing with the consequences of high blood pressure.

Knowing your risk is only half the battle

For me, the bigger issue is not simply that we’re identifying health risks earlier. It’s what we’re doing once we’ve identified them.

We spend a great deal of time in healthcare encouraging people to go for screenings, check their blood pressure, monitor their glucose levels and understand their health risks. And rightly so. Early detection remains one of the most valuable tools we have.

But I sometimes wonder whether we’ve become so focused on getting people screened that we haven’t paid enough attention to what happens afterwards. Some of our wellness data suggests that individuals who recorded elevated health indicators continued to present with elevated readings a year later.

Think about what that means. Someone has been told that their blood pressure is too high or that their glucose levels need attention. They have the information. They know there is a potential problem. Yet a year later, the risk is still there.

It raises an uncomfortable question: Are we doing enough to help people act on what they know?

I don’t believe the answer lies in simply telling people to eat better, exercise more or lose weight. Most South Africans have heard that advice countless times. Knowing what to do and being able to do it consistently are two very different things.

Healthy choices don’t happen in isolation. They are influenced by people’s circumstances, the demands on their time, their access to healthcare and the support available to them.

A person working long hours, commuting for several hours a day and trying to support a family may understand the importance of regular exercise and healthy eating. But understanding the importance of something doesn’t automatically make it easy to achieve.

This is where I believe our approach to preventative healthcare needs to evolve. Screening should be the beginning of a conversation, not the end of one. When someone is identified as being at risk, there should be a clear path towards appropriate medical advice, ongoing monitoring and practical support that helps them make sustainable changes. However, that responsibility cannot sit with individuals alone.

Workplace wellness needs to go beyond wellness days

Medical schemes, healthcare providers and employers all have a role to play in making prevention more accessible and meaningful.

I am particularly interested in the role of employers because so many of these health risks are being identified during people’s working years.

We often speak about workplace wellness in terms of employee benefits, wellness days and annual health screenings. These initiatives certainly have their place, but I think we need to ask whether they are making a lasting difference.

If an employee discovers during a workplace screening that they have elevated blood pressure, what happens next? Is there support to help them manage it? Are they encouraged to seek medical advice? Is there any follow-up?

Or does everyone simply return to their desks and carry on until the next wellness day?

It’s worth thinking about, particularly when we consider the impact that unmanaged chronic conditions can have on absenteeism, productivity and people’s overall quality of life.

There is also a much bigger economic consideration.

When someone develops a chronic condition at 35 rather than 65, they may face decades of treatment, monitoring and potential complications. Multiply that across a population already experiencing high rates of hypertension, obesity and diabetes, and the implications for healthcare costs become difficult to ignore.

In a country where only 15.5% of the population belongs to a medical scheme and the majority depend on the public healthcare system, we simply cannot afford to keep responding to preventable health risks only once they have become serious medical problems.

We cannot afford to wait until people become ill

I don’t pretend that prevention is easy, nor do I believe every chronic condition can be avoided. Genetics, environmental factors and broader socioeconomic circumstances all influence our health.

But I do believe we have an opportunity to do things differently.

We have access to more health information than ever before. We can identify many risk factors earlier, and we understand far more about the interventions that can help people manage them.

What we need now is to become better at turning that knowledge into action.

For me, that is where the future of healthcare lies. Not only in developing better ways to treat illness, but in creating the support systems that help people stay healthier for longer.

And perhaps we also need to change the way we think about our own health. You shouldn’t have to reach a certain age, experience a health scare or receive a diagnosis before taking your health seriously.

If there is one thing our data has reinforced for me, it is that chronic disease doesn’t necessarily wait until we’re older. Neither should prevention.

Specialist Shortfalls up 74% in 5 Years, yet 4 in 5 Medical Aid Members Have No Gap Cover

As 2027 medical scheme premiums rise, members moving to cheaper plans face even bigger out-of-pocket costs

Photo by Cottonbro on Pexels

Tuesday, 17 November 2026, Johannesburg: With significant increases coming in 2027, many medical scheme members will need to decide whether to buy down to a cheaper option. However, many aren’t considering how much specialist fees have risen while medical scheme payouts have lagged.

Kaelo’s claims analysis shows that between 2021 and 2026, specialist fees rose 50% while the amounts medical schemes pay rose just 24%, lifting the typical shortfall on a specialist account by 74% over the 5-year period. Specialists set their own fees and schemes set their own rates, so the patient must settle the difference. Only about one in five scheme members has gap cover, which would cover this shortfall.

“Even members who stay on the same plan face larger shortfalls every year, and buying down increases the exposure,” says Sian MacGregor, sales director at Kaelo. “Our actuaries have shown that gap cover is not an optional extra these days, given the dynamics at play in the medical scheme landscape. It has become a necessary add-on to medical aid.”

Kaelo’s modelling shows that once a typical earner has covered their monthly expenses, they’re left with about R850, and that’s all they would have to put towards an unexpected medical bill. At that rate, the average shortfall on childbirth (R18 500) takes 22 months to repay, uterine scarring (R19 000) takes 23 months, and spinal stenosis (R30 000) takes three years. These are just three examples of common medical procedures; others can cost a lot more.

For example, a young woman with endometriosis, on a medical scheme, will face about R35 000 in shortfalls and co-payments for surgery. On a first-job salary of R20 000 a month, and without gap cover, the operation would likely be put off, but delayed intervention has consequences. Postponing treatment for uterine scarring can raise miscarriage risk in a later pregnancy by up to 33%, while a delayed colonoscopy has major implications for survival rates if cancer is found.

Kaelo has paid the annual maximum gap cover of about R210 000 on numerous claims in the past year, including cardiac and vascular surgery.

How an employer offers gap cover affects what staff pay. In one Kaelo employer group, gap cover moved from voluntary to compulsory for staff on a medical scheme. Covered employees rose from an average of 960 to nearly 3,600. Total monthly claims tripled, and that year 166 more employees who previously could not afford care could now access and claim from gap cover. At the same time, the average cost per covered employee fell by 16%.

“When cover is voluntary, the people who sign up are mostly those who already expect to claim, so costs and premiums climb,” says MacGregor. “When it is the default, the cost is spread across a bigger, healthier pool.” Kaelo projects that within five years, premiums for a group where cover is the default will be 30% to 50% lower than for the same cover offered voluntarily. Policyholders also get Dis-Chem Better Rewards, a benefit that helps offset the premium.

In addition to covering medical aid shortfalls, Kaelo Gap pays hospital co-payments upfront, so members don’t have to find the cash before a planned procedure. After a claim, trained counsellors call members to check on their overall wellbeing, such as phoning new mothers or offering support on a cancer diagnosis.

Kaelo Gap has grown about 11% year to date, across corporate and individual clients.

Members who plan to buy down on their medical scheme plan should check that their gap option is still appropriate, MacGregor advises. One Kaelo Gap option pays up to an additional 500% of the scheme rate, which may suit a comprehensive plan, while a basic plan may call for another option, which pays up to an additional 600%. Individual policies usually have a three-month waiting period, so arrange cover well before you need treatment. Individual cover starts from R219 a month.

Review Finds Insufficient Evidence to Back Medical Cannabis for Insomnia

Photo by Andrea Piacquadio

A new Cochrane review finds that existing evidence is too uncertain to determine whether medical cannabis improves sleep or daytime functioning in people with insomnia.

Insomnia is a common sleep disorder that makes it hard to fall asleep, stay asleep, or wake up not feeling refreshed. It can have a severe impact on a person’s quality of life and make a person much more vulnerable to developing anxiety or depression over time. 

Existing treatment options include cognitive behavioural therapy and drugs, including antidepressants and antipsychotics, but these vary in success. 

In recent years, there has been growing interest in medical cannabis as an alternative treatment for insomnia for its reported benefits in improving sleep. In clinical settings, this typically involves controlled, tested ratios of THC and CBD in the form of tablets, sprays or oils. However, the use of medical cannabis for insomnia remains contentious, and evidence is limited. 

No clear evidence that medical cannabis helps

Led by researchers from The Cochrane Associate Centre at the Universidad Hospital Italiano de Buenos Aires and University of Manitoba, the review included 9 studies involving 537 adults aged 18 to 76 who were treated for insomnia. Most studies focused on people with primary insomnia rather than insomnia linked to other health conditions. Eight of the nine trials compared regulated medical cannabis to a placebo; one compared it to the antidepressant amitriptyline.

Medical cannabis showed little to no clinically meaningful improvement in sleep quality and satisfaction, total sleep time, or daytime functioning compared with placebo. 

Participants taking medical cannabis were substantially more likely to experience mild adverse events, such as a dry mouth and dizziness, than those on placebo; but this was based on a small pool of studies.

Medical cannabis somewhat improved quality of life, but certainty is very low, and pooled results were compatible with anything from a slight worsening to a large improvement.
 

The main message is that the research currently available is not sufficient to reliably answer whether medical cannabis helps people with insomnia.

– Dr Lucia Varela, University of Manitoba


Dr Lucia Varela, lead author of the study from the University of Manitoba, Canada, says: “This does not mean that medical cannabis is ineffective. It means that, based on the evidence we have, we cannot draw reliable conclusions about its effectiveness for insomnia in the general population.”

Poor trials downgrade the evidence

The overall quality and certainty of the evidence were rated very low to low, largely due to risk of bias in the underlying studies, inconsistent results between trials, and small sample sizes. 

Studies varied a lot in the type of cannabis product used, which limited comparability, and the longest study only followed participants for 12 weeks. This means we can’t say much about the long-term effects.

The available data was also not very representative of broader patient groups. The data were heavily skewed towards younger people and women (72.66% of participants). Therefore, the findings may not be as applicable to men, older adults, and those with comorbidities.

The authors conclude that the evidence remains weak and uncertain, highlighting the need for higher-quality research before medical cannabis can be recommended for insomnia.

“The evidence is too weak and uncertain to draw firm conclusions about the use of medical cannabis for insomnia,” says Dr Luis Garegnani, senior author from Universidad Hospital Italiano de Buenos Aires, Argentina. “Rather than viewing the findings as either an endorsement or a rejection of medical cannabis, clinicians and patients should recognise the uncertainty and consider individual circumstances while better evidence is generated.”

By Mia Parkinson

Read the review

Source: Cochrane

‘Fossil Record’ in Stored Blood Samples Lets Scientists Trace Leukaemia back Decades Before Diagnosis

SAG Leukaemia. Credit: Scientific Animations CC0

Scientists have reconstructed how acute myeloid leukaemia (AML) develops over the decades before diagnosis, showing that in two-thirds of cases the first cancer-driving mutation had been acquired before the age of 20 – more than 50 years before diagnosis. 

Serial blood samples are a fossil record of the blood’s evolution. They let us go back in time and reconstruct when each mutation arose and how fast it grew

Jamie Blundell

The discovery could help predict whether an individual will develop the disease years – or even decades – before symptoms arise, raising the possibility of preventing the disease before it develops.

In research published today in Nature, a team at the University of Cambridge and University College London (UCL) used blood samples collected annually, some dating back 15 years before diagnosis, as a ‘fossil record’ of the disease’s development, tracing it step by step. Using ultra-sensitive DNA sequencing and mathematical modelling, they estimated when each mutation arose and how quickly the affected cells multiplied and competed with other blood cells in the years prior to AML diagnosis.

AML is an aggressive blood cancer affecting around 2,700 people in the UK each year. Only around one in six survive five years after diagnosis. Many healthy older people carry blood cells with mutations also found in leukaemia, a condition known as clonal haematopoiesis, but only a small proportion develop AML. What has not been clear is why, because the process has never been tracked year by year in the run-up to diagnosis.

The researchers used samples from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), in which around 50,000 women gave a blood sample every year for up to 11 years. The team studied 47 women who later developed AML, at an average age of 72, alongside matched samples from 46 women who stayed blood cancer-free.

This first mutation, acquired before age 20 in two-thirds of the women who developed AML, was followed by decades of slow growth – cells carrying it took years to double in number. Each additional mutation increased their growth rate around two- to three-fold, with cells carrying four cancer-driving mutations doubling in a matter of weeks.

The growth of these groups of cells, known as clones, proved remarkably predictable. Once a clone carrying a cancer-driving mutation was established, it expanded at a steady rate, slowing only when it ran out of room or was overtaken by a faster-growing clone. In practice, this means a clone’s growth rate, measured from a few blood samples today, can be used to estimate how large that clone may become years and even decades into the future.

In at least a third of the AML cases, a clone had come to dominate the blood years before diagnosis, a phenomenon known as a ‘somatic sweep’. No such sweeps were seen in the women who remained blood cancer-free. The team confirmed the link with AML risk using UK Biobank data, finding that people with these sweeps were at greatly increased risk of developing the disease. The findings highlight the importance of recognising this potential warning sign, which standard genetic analysis often overlooks by mistaking these mutations for inherited variants.

Professor Jamie Blundell from the Early Cancer Institute at the University of Cambridge, who led the study, said: “Serial blood samples are a fossil record of the blood’s evolution. They let us go back in time and reconstruct when each mutation arose and how fast it grew. What surprised us most is how predictable the growth of these clones is. Once a clone is established, its growth rate today tells you where it will be years, even decades, from now.”

He added: “Because the growth is exponential, even modestly slowing a high-risk clone over the decade or more before diagnosis could substantially reduce the chance it becomes leukaemia. This opens up strategies we can exploit to prevent these clones ever becoming leukaemia.”

Dr Caroline Watson, also from the Early Cancer Institute, and first author of the study, said: “As a haematologist, I’ve seen how suddenly AML can change someone’s life. This study shows that the changes leading to AML can build over decades, with the affected cells growing in surprisingly predictable ways.”

Dr Watson is also an Honorary Consultant Haematologist and sees patients at the Cambridge Clonal Haematopoiesis Clinic at Addenbrooke’s Hospital, the first clinic focusing on leukaemia prevention in Europe. She added: “At our clinic, we already assess and monitor people who carry blood-cell mutations that increase their risk of leukaemia. Today’s findings give us real hope of improving how we identify which of them are at greatest risk and point to a window in which prevention could one day be possible.”

Professor Usha Menon, from the UCL Institute of Clinical Trials and Methodology, who led UKCTOCS, said: “While UKCTOCS was designed to assess ovarian cancer screening, a key outcome was the establishment of a unique bioresource of serial serum samples. This resource has provided unprecedented opportunities to study how cancers develop over time and to discover and validate biomarkers for earlier detection. We owe an enormous debt of gratitude to the participants whose willingness to contribute their samples and data over many years made this possible. Their generosity is the foundation of this achievement.”

The women were diagnosed with AML between the ages of 53 and 83, and the study did not include samples taken at time of diagnosis. In around one in five cases, expanding populations of mutated cells were not detectable until one to two years before AML diagnosis, suggesting that some cases may offer a shorter warning period.

The findings point towards opportunities for early detection and prevention. The team’s modelling suggests that even a small reduction in a clone’s growth rate, compounded over the ten or more years between the second mutation and diagnosis, could substantially reduce the risk of progression to leukaemia. This raises the possibility of preventative treatments that slow these cells’ growth before leukaemia develops. Testing whether this can be achieved safely and effectively in people identified as high risk is the team’s next step.

The research was largely funded by UK Research & Innovation and Cancer Research UK.

The University of Cambridge and Addenbrooke’s Charity are fundraising for Cambridge Cancer Research Hospital, which will include the Early Cancer Institute Research Clinic, where detecting cancer at its earliest stages will be a key goal. Set to be built on the Cambridge Biomedical Campus, the hospital will bring together clinical excellence from Addenbrooke’s Hospital and world-leading researchers at the University of Cambridge. The research that takes place there promises to change the lives of cancer patients across the UK and beyond. Find out more here.

Reference

Watson, CJ, et al. Evolutionary dynamics in the years preceding acute myeloid leukaemia. Nature; 11 Nov 2026; DOI: 10.1038/s41586-026-11269-x


Creative Commons License.
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Source: University of Cambridge

Single Iron Infusion Improved Exercise Capacity in HFpEF

Iron deficiency is a common challenge in people with heart failure with preserved ejection fraction
A randomised trial found that intravenous iron repletion led to functional benefits after 12 weeks for these patients

Right side heart failure. Credit: Scientific Animations CC4.0

A new study by investigators from the Mass General Brigham Heart and Vascular Institute found that a single iron infusion improved exercise capacity in people with heart failure with preserved ejection fraction (HFpEF) and iron deficiency. The findings suggest that replenishing iron could help address the physical limitations associated with this condition. Results were presented at the 2026 American Heart Association Scientific Sessions and published simultaneously in Circulation.

The IRON-MET HFpEF trial enrolled 65 participants with symptomatic HFpEF and iron deficiency, which affects more than 50% of patients with HFpEF. Their median age was 68 years, and 72% of participants were women. For the study, 44 participants were randomized to receive one 1000mg IV dose of ferric derisomaltose and 21 to receive placebo. Iron was administered intravenously because previous studies have demonstrated that oral iron is not beneficial in patients with other forms of heart failure, likely due to poor gastrointestinal absorption.

All participants underwent cardiopulmonary exercise testing before and 12 weeks after the infusion. At 12 weeks, peak oxygen uptake or VO2, a key indicator of cardiorespiratory fitness, improved by approximately 10% in the intervention group and was unchanged in the placebo group.

“Patients living with HFpEF are burdened with severe limitations in exercise tolerance,” said lead author Gregory D. Lewis, MD, director of Heart Failure at the Mass General Brigham Heart and Vascular Institute and professor of Medicine at Harvard Medical School. “In the first study to comprehensively evaluate exercise response patterns to iron repletion in patients with HFpEF and iron deficiency, we found that ferric derisomaltose improved multiple measures of exercise capacity.”

Measurements of the bioavailability of iron in the blood improved with intravenous iron, as did pre-specified secondary measures of exercise capacity, including 6-minute walk distance, VO2 at the anaerobic threshold, and New York Heart Association Functional Class, compared with those who received placebo. However, the authors note that patient-reported health scores, based on a comprehensive questionnaire, did not differ significantly between groups. There were no serious adverse events associated with the iron supplementation.

As the study was conducted in a small, predominantly white population and participants were assessed at 12 weeks, the authors advocate for further studies to determine whether IV iron has benefits in diverse populations and whether these benefits last over longer time periods.

“The improvement we observed in peak VO2 represents a clinically meaningful increment for patients with heart failure,” said senior author Rajeev Malhotra, MD, who is Associate Director of the Cardiopulmonary Exercise Laboratory at the Mass General Brigham Heart and Vascular Institute and associate professor of Medicine at Harvard Medical School. “The next step is to determine whether IV iron can improve long-term clinical outcomes in patients with HFpEF.”

Source: Mass General Brigham

Could These Drugs Improve Survival in ARDS?

Photo by Anna Shvets

A clinical trial starting on Nov. 19 at UC San Francisco could lead to the first precision medicines for a rapidly progressing, life-threatening breathing disorder.

The disorder, acute respiratory distress syndrome (ARDS), affects 1 in 10 patients in intensive care units (ICUs) and usually follows pneumonia, severe infection, or accident-related trauma. ARDS causes inflammation and fluid buildup in the lungs, making it difficult for oxygen to enter the bloodstream.

Currently, treatment for ARDS largely consists of supportive care, including mechanical ventilation, which delivers air enriched with oxygen into the lungs and can be lifesaving but may also worsen lung injury. For 35% to 45% of patients, ARDS is fatal.  

Can a patient walk independently? Are they able to return to work?

Michael Matthay, MD, professor of medicine and anaesthesia at UCSF

The PANTHER trial is funded by the U.S. Department of Defense and will run at 10 institutions nationwide. Additional sites will be located abroad. The study builds on years of research by Carolyn Calfee, MD, and Michael Matthay, MD, professors of medicine and anesthesia at UCSF and co-directors of the Center for Precision Research in Critical Care, a new center dedicated to improving patient outcomes in the ICU through implementation of precision medicine.

Their research has identified two biological forms of ARDS, hyperinflammatory and the less inflamed hypo-inflammatory, raising the possibility that precision medicine for each could lead to better outcomes.  

“We found that some treatments that appeared to improve survival in one form showed no benefit when patients with both forms were analysed together,” said Calfee, co-principal investigator of the UCSF site and one of the leads of the global PANTHER trial. 

Researchers plan to enroll 300 patients at the U.S. sites.  

Patients will first receive a blood test for biomarkers that classify them as having hyperinflammatory or hypo-inflammatory ARDS. One-third will be randomly assigned to receive usual care, which may include lung-protective mechanical ventilation, positioning patients on their stomachs to improve oxygen levels, and managing fluids to reduce fluid buildup in the lungs.

The remaining patients will receive usual care plus one of two drugs. The first, simvastatin, is widely used to lower cholesterol and also has broad anti-inflammatory effects; while baricitinib, which targets specific inflammatory pathways and is approved to treat rheumatoid arthritis, has shown some benefit in treating ARDS resulting from severe COVID-19.

PANTHER is an adaptive trial platform that enables the study to change as evidence accumulates. Promising new drugs can be added, while drugs that are shown to be ineffective will be dropped.  

The study will measure survival and the number of days during the first 28 days that patients live without major life support treatments, such as mechanical ventilation or drugs to maintain blood pressure.

“Additionally, we will be looking at the extent to which a patient can recover,” said Matthay, co-principal investigator of the UCSF site and a member of PANTHER’s biobanking team, which collects blood samples. “Can a patient walk independently? Are they able to return to work? Are they recovering their cognitive skills, and do they have the muscle strength to perform everyday tasks?”

Many people who survive ARDS face long-term cognitive impairment and significant physical limitations, according to the National Heart, Lung, and Blood Institute. 

By Suzanne Leigh

Source: University of California San Francisco